Inhaled Corticosteroid Management After Acute Asthma Exacerbation Discharge

Discharge Medication Regimen

All patients discharged after an acute asthma exacerbation should receive inhaled corticosteroids at a dose higher than their pre‑admission regimen, with therapy started at least 48 hours before discharge. 1
Short‑acting β‑agonists (e.g., albuterol) must be prescribed for as‑needed symptom relief at discharge. 1

Budesonide inhalation suspension (0.25 mg or 0.5 mg) delivered via nebulizer is an appropriate option for post‑discharge maintenance therapy. 2
For patients with moderate‑to‑severe exacerbations or high risk of relapse, prescribe the higher end of the recommended dose range (e.g., fluticasone propionate 200‑250 µg daily or equivalent) or consider an ICS/LABA combination. [3][4]

Initiate inhaled corticosteroid therapy at least 48 hours before hospital discharge. 1
Replace nebulizer therapy with standard inhaler devices 24‑48 hours before discharge unless a home nebulizer is clinically required. 1
Verify and document proper inhaler technique before discharge to ensure effective medication delivery. 1

In patients with a history of severe exacerbations, frequent emergency department visits, or prior hospitalizations, prescribe an ICS/LABA combination rather than ICS alone. [3][4]
Available evidence‑based combinations include fluticasone propionate/salmeterol and budesonide/formoterol. [3][4]
Adding a long‑acting β‑agonist to inhaled corticosteroid therapy is more effective than simply increasing the ICS dose for preventing future exacerbations in moderate‑to‑severe asthma. [3][4]

High‑dose inhaled corticosteroids alone should not replace oral corticosteroids in most patients after an acute exacerbation. 5
Current evidence is insufficient to support high‑dose ICS as a substitute for oral corticosteroids in the emergency department or at discharge. 5

Provide each patient with a peak‑flow meter and training on its proper use. 1
Supply a written asthma action plan that specifies PEF thresholds for stepping up therapy, contacting a clinician, or seeking emergency care. 1
Ensure inhaler technique is verified and documented before discharge. 1
Arrange follow‑up visits:

Note: Strength of evidence was not explicitly stated in the source material.

The American Thoracic Society recommends that asthma patients must meet specific clinical stability markers before discharge, including peak expiratory flow (PEF) >75% of predicted or personal best value, diurnal PEF variability <25%, and no nocturnal symptoms 6, 7
Patients must have been on discharge medications for at least 24 hours before discharge, according to the American College of Chest Physicians 8, 7
Nebulizers should be replaced by standard inhaler devices 24-48 hours before discharge, unless a home nebulizer is required, as suggested by the European Respiratory Society 6, 7

The National Asthma Education and Prevention Program recommends prescribing prednisolone 30-60 mg daily for adults for 3-10 days 8
For children, prescribe 1-2 mg/kg/day (maximum 60 mg/day) for 3-10 days, according to the American Academy of Pediatrics 8
Inhaled corticosteroids (ICS) should be prescribed at a higher dosage than before admission, as recommended by the Global Initiative for Asthma 6, 8
ICS treatment must be started at least 48 hours before discharge, according to the British Thoracic Society 6, 7

Every patient must receive a peak flow meter and comprehensive training on its use before discharge, as recommended by the American Lung Association 6, 8
A written self-management plan must include specific PEF values at which to increase treatment, when to call their doctor, and when to return to the hospital or emergency department, according to the National Institutes of Health 6, 8

Before discharge, review the circumstances that led to admission, including avoidable precipitating causes or allergen exposure, patient compliance with regular treatment, and reaction to worsening asthma, as suggested by the American Thoracic Society 6, 9

Mandatory follow-up schedule must be arranged before discharge, including a primary care physician visit within 1 week of discharge and a respiratory physician appointment within 4 weeks, according to the American College of Chest Physicians 6, 8, 7

Inadequate duration or dosing of systemic corticosteroids increases relapse risk, as warned by the American Academy of Allergy, Asthma, and Immunology 8, 7
Discharging patients before they have been on medications for 24 hours increases relapse risk, according to the Society of Hospital Medicine 8, 7
Failing to increase ICS dose above pre-admission levels may lead to treatment failure, as cautioned by the European Respiratory Society 6, 8
Not providing a written action plan significantly increases relapse risk, as emphasized by the National Asthma Education and Prevention Program 8, 7